Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Cervical Cancer Diagnostics Market $13.7 Billion by 2029

The global market for cervical cancer diagnostics expected to reach $13.7 billion by 2029, expanding at a CAGR of 5.4% over the forecast period, driven by increasing prevalence and incidence of HPV infections, increasing cervical cancer screening awareness programs, and technological advancements.

  • Other factors contributing to market growth include increasing demand for diagnostic and advanced screening technologies, high adoption rate of preventive diagnostic techniques among the population and increasing levels of patient safety measures.
    • However, rising cost of development for assay kits and devices, stringent regulatory approvals and low awareness among the population are restraining the growth of cervical cancer diagnostics market.
Global Cervical Cancer Diagnostics Market

Cervical cancer is caused due to human papillomavirus (HPV) infection and Worldwide, it is the fourth-most common cause of cancer and the fourth-most common cause of deaths from cancer in women. Primary prevention and screening are by far the most effective modalities for decreasing the healthcare burden and mortality attributable to cervical cancer. HPV and cervical cancer have a significant global impact. Research and innovations related to detection and treatment are key in reducing their burden worldwide.

  • Globally, there are more than 500,000 new cases of cervical cancer annually. Approximately 250,000 women die of cervical cancer annually.  In the United States, about 4,000 women die from cervical cancer annually with African Americans, Hispanics, and women in low-resource areas having higher disparities in evidenced-based care and a much higher mortality rate
  • According to American Cancer Society (ACS), among females worldwide the most common cancer sites were either breast or cervical cancer, with the exception of China (lung), South Korea (thyroid), and Mongolia and Vietnam (liver).
    • The cervical cancer diagnosis involves a colposcopic examination of the cervix followed by a Pap smear test and a HPV DNA test to determine the infection by HPV type.
      • Screening can prevent cervical cancer by detecting precancerous lesions. As screening has become more common, precancerous lesions of the cervix are detected far more frequently than invasive cancer.
        • Two vaccines against HPV have been approved in the major markets: Merck & Co.’s Gardasil and GlaxoSmithKline’s Cervarix.

The global cervical cancer diagnostics market report estimates the market size ($million 2019 to 2029), market share, growth trends and forecast (CAGR% 2023 to 2029).

The global market for cervical cancer diagnostics segmented by diagnostic test (cervical biopsy, colposcopy, endocervical curettage, HPV typing, loop electrosurgical excision procedure, pap smear testing), imaging test for stage detection (computed tomography or computed axial tomography, magnetic resonance imaging, positron emission tomography, chest X-ray, others), and geography.

Cervical Cancer Diagnostics Market
  • Based on the diagnostic tests, the pap smear testing segment accounted for the largest share of total market, followed by the colposcopy testing segment.
    • The Papanicolaou test or Pap smear test is a preventive diagnostic technique for cervical screening used for the detection of pre-cancerous and cancerous cells in the vagina and cervix.
      • Pap smear test is not a cancer-diagnosing tool, but rather, is a preventive screening tool used to discover early symptoms that might become cancerous in future.
        • In addition, Pap smear tests help to diagnose HIV infections and monitor the exposure levels of diethylstilbestrol (DES) before birth.
  • The HPV typing segment anticipated to grow at the fastest rate during the next few years.
    • HPV test is usually performed to check high-risk HPV infection, which might cause formation of cancerous cells on the cervix.
      • This test identifies the genetic material (DNA or mRNA) of the virus responsible for causing cervical cancer in women.
    • HPV test can be used in conjunction with Pap test, when the result outcomes of the Pap smear tests are abnormal.
      • At present, digene HC2 High-Risk HPV DNA Test, developed and commercialized by Qiagen N.V., is the clinically available and widely used assay on the market. The assay is based on signal-amplified hybridization microplate technology and is the only FDA approved HPV test.

The global cervical cancer diagnostic testing market research report is further divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

  • Geographically, the North America region dominated the global market for cervical cancer diagnostics, followed by the Europe region.
    • In the United States and other developing countries, most screening and diagnostic efforts are directed towards early identification of high-risk human papillomavirus (HPV) lesions through HPV testing and pap smears.
      • Factors driving the growth in developed countries are increasing adoption rate of preventive diagnostic techniques, government initiatives on cancer awareness, high prevalence and incidence rate of cervical cancer, and increasing involvement in research and development in personalized medicines and genetic biomarkers.
  • The Asia Pacific market expected to witness the fastest growth rate during the forecast period, attributed to increasing incidence rate of cervical cancer and HPV infection coupled with physician preference for frequent preventive cervical health check-ups.
    • Moreover, increasing number of patients suffering from sexual transmitted diseases (STI) in the Southeast Asian countries are expected to drive the demand for cervical cancer diagnostic tests in this region.
      • In developing countries, cervical cancer is one of the most important health problems for women. The most efficient and cost-effective screening techniques in low-resource countries include visual inspection using either acetic acid or Lugol’s iodine and DNA testing for HPV in cervical cell samples.
        • New low-tech methods of screening for cervical cancer with direct visualization, acetic acid, and oftentimes immediate treatment, may be cost-effective in developing countries.
      • The Pap test is the most widely used cervical cancer screening method. However, many low-resource countries do not have the technical and public health infrastructure to support Pap testing for cervical cancer.
        • Therefore, increasing access to and improving quality of screening programs in the high-risk age group of 35-50 years has been identified as a key component of effective programs for the early detection of cervical cancer in low-resource settings.

The report also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent acquisitions and alliances.

Major competitors operating in the global cervical cancer diagnostic testing market and included in this report are Abbott Laboratories, Inc., Becton, Dickinson and Company, Hologic, Inc., Roche Holding AG, Quest Diagnostics, Inc., BioSciCon, Inc., Qiagen N.V., Femasys, Inc., Zilico Ltd., Guided Therapeutics, Inc., and OncoHealth Corp.

  • Diagnostic Test
    • Cervical Biopsy
    • Colposcopy
    • Endocervical Curettage (ECC)
    • Human Papilloma Virus (HPV) Typing
    • Loop Electrosurgical Excision Procedure (LEEP)
    • Pap Smear Testing
    • Others
  • Imaging Test for Stage Detection
    • CT or CAT (Computed Axial Tomography)
    • MRI (Magnetic Resonance Imaging)
    • PET (Positron Emission Tomography)
    • Chest X-ray
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Abbott Laboratories, Inc.
    • Becton, Dickinson and Company
    • BioSciCon, Inc.
    • Femasys, Inc.
    • Guided Therapeutics, Inc.
    • Hologic, Inc.
    • OncoHealth Corp.
    • Qiagen N.V.
    • Quest Diagnostics, Inc.
    • Roche Holding AG
    • Zilico Ltd.

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com